<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82349">
  <stage>Registered</stage>
  <submitdate>15/10/2007</submitdate>
  <approvaldate>18/10/2007</approvaldate>
  <actrnumber>ACTRN12607000534482</actrnumber>
  <trial_identification>
    <studytitle>A Prospective Study Investigating the Impact of Definitive Chemoradiation in Locally and/or Regionally Advanced Squamous Cell Carcinoma of the Skin</studytitle>
    <scientifictitle>A Prospective Nonrandomised Study Investigating the Impact of Definitive Chemoradiation Using Cisplatin or Carboplatin on Complete Response Rate in Patients with Locally and/or Regionally Advanced Squamous Cell Carcinoma of the Skin</scientifictitle>
    <utrn />
    <trialacronym>CRUST</trialacronym>
    <secondaryid>nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Squamous Cell Carcinoma of the Skin</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Cisplatin 40mg/m2 given intravenously once per week concurrent with radiation therapy for 6 weekly doses
Carboplatin at a dose of AUC2 given intravenously once a week for 6 weekly doses concurrent with radiotherapy, for patients where cisplatin is contraindicated</interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Complete Response Rate</outcome>
      <timepoint>8weeks after completion of therapy</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival</outcome>
      <timepoint>3years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease-free Survival</outcome>
      <timepoint>3years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Toxicity according to Common Toxicity Criteria Version 3.0</outcome>
      <timepoint>Acute toxicity monitored daily for the 7 weeks of radiation therapy, then at 4,8 &amp; 12 weeks after completion of therapy. Late toxicity monitored every 2months for first year and every 3rd month for thereafter</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with cutaneous squamous cell carcinoma with locally-advanced disease at the primary site +/-nodal metastases, or advanced regional node metastases of presumed skin origin.
Disease deemed unsuitable for surgical resection</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>-2147483648</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Co-morbid conditions precluding safe administration of trial therapy
Previous chemo- or radiotherapy to head and neck region precluding re-treatment
Pregnancy/lactation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>N/A</concealment>
    <sequence>N/A</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/01/2008</anticipatedstartdate>
    <actualstartdate>26/01/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/02/2016</actualenddate>
    <samplesize>30</samplesize>
    <actualsamplesize>21</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>29/02/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <postcode>4029</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Michelle Nottage</primarysponsorname>
    <primarysponsoraddress>Royal Brisbane and Women's Hospital
Herston Rd
Herston, 4029</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Alessandra Francesconi</sponsorname>
      <sponsoraddress>Royal Brisbane and Women's Hospital
Herston Rd
Herston, 4029</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Sabe Sabesan</othercollaboratorname>
      <othercollaboratoraddress>Dept of Medical Oncology, Townsville Cancer Centre
Townsville Hospital</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Phase 2

This is a study of the effectiveness and toxicity of chemoradiation
therapy for skin cancer (squamous cell carcinoma).
 
Who is it for?
You can join this study if you have squamous cell skin cancer that
cannot be treated surgically. 

Trial details
Participants will receive chemotherapy with the drugs cisplatin or carboplatin once per week for 6 weeks as well as daily radiotherapy. There is no
control group in this study. Participants' response to treatment will be
measured 8 weeks after treatment is completed. Side effects will be
monitored during treatment, at 4, 8 and 12 weeks after treatment is
completed, and then every 2 months for the first year, and every three
months after that.  Overall survival and disease free survival will be
measured after 3 years.  

The study aims to document the effectiveness and toxicity of treatment
with combined chemotherapy and radiotherapy.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Brisbane and Women's Hospital HREC</ethicname>
      <ethicaddress>Herston Rd
Herston</ethicaddress>
      <ethicapprovaldate>20/01/2008</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>25/10/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Townsville Health Service District Institutional Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>25/11/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr Michelle Nottage</name>
      <address>Royal Brisbane and Women's Hospital
Herston Rd
Herston, 4029</address>
      <phone>7 36368111</phone>
      <fax />
      <email>michelle.nottage@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Michelle K Nottage</name>
      <address>Royal Brisbane and Women's Hospital
Herston Rd
Herston, 4029</address>
      <phone>7 36368111</phone>
      <fax />
      <email>michelle.nottage@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Michelle Nottage</name>
      <address>Royal Brisbane and Women's Hospital
Herston Rd
Herston, 4029</address>
      <phone />
      <fax />
      <email>michelle.nottage@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Michelle Nottage</name>
      <address>Cancer Care services
Royal Brisbane and Women's Hospital 
Herston
Queensland 4029</address>
      <phone>61 7 36468111</phone>
      <fax />
      <email>michelle.nottage@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>